Category: Medmonitor

90 posts found

FDA Approves Hulio for Rheumatoid Arthritis and More

Subcutaneous injections of the new biologic, adalimumab-fkjp, were approved for seven indications.

Elyxyb (celecoxib) is an NSAID for the acute treatment of migraine with or without aura.

New developments with diagnostic testing and the use of chloroquine and hydroxychloroquine.

Anjeso and a new Advil formulation target pain, while Nurtec™ and Vyepti™ target migraines.

A new seizure drug has been approved, and a nerve growth drug advances in clinical trials.

Migraine, arthritis, and insomnia drug approvals, and a gabapentinoids safety warning.

A biosimilar to Humira is approved, the FDA Fast Tracks a PTSD drug, and more.

A previous gastrointestinal drug recall expands, while a new recall for an anxiety drug is issued.

Indicated for various gastrointestinal concerns, these recalls could impact certain workers’ comp patients.

NKTR-181 (loxicodegol) was to receive an approval decision by August 29th, but a reevaluation of opioid policy has resulted in a delay.

Nine generic versions of Lyrica (pregabalin) have been approved for the treatment of five different medical conditions.

Generic versions of Ultram (tramadol hydrochloride) tablets and Dyloject (diclofenac sodium) injections have been approved by the FDA.

Orphengesic Forte has received a decision date of August 14, 2019.

The life saving antidote for opioid overdose will soon be available in a consumer-friendly, generic nasal spray.

New changes to REMS safety programs will require stronger treatment documentation and oversight.

Prev 1 2 3 4 5 6 Next